Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

80.11 -4.76 (-5.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
I’m Not Worried About This Pullback
Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree. 
Via Talk Markets
Topics Cryptocurrencies Stocks / Equities
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
From GeneDx
Via Business Wire
IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development
GeneDx provides whole and exome gene sequencing to identify rare diseases. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Focus On High Cash Flow Companies. You Are The Company You Keep.
There are too many stocks acting well to expect a bear market right now. 
Via Talk Markets
Topics Stocks / Equities
Why NASDAQ:WGS qualifies as a high growth stock.
Why the high growth investor may take a look at GENEDX HOLDINGS CORP (NASDAQ:WGS). 
Via Chartmill
The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts
Via Benzinga
Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly
Energy plays, a biotech and a brokerage also are flashing buy signals or setting up. 
Via Investor's Business Daily
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday
US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters. 
Via Benzinga
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
From GeneDx
Via Business Wire
Best Performing Stocks Of 2024
A look at the some of best performing stocks in 2024 of current Russell 3,000 members. 
Via Talk Markets
Topics Stocks / Equities
The Top 5 Mid Cap Stocks Of 2024
These high-fliers are on the leading edge of innovation. 
Via Talk Markets
Topics Stocks / Equities
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From GeneDx
Via Business Wire
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
From GeneDx
Via Business Wire
GeneDx to Participate in Upcoming Investor Conference
From GeneDx
Via Business Wire
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
From GeneDx
Via Business Wire
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
From GeneDx
Via Business Wire
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Via The Motley Fool
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
From GeneDx
Via Business Wire
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
From GeneDx
Via Business Wire
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue. 
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
From GeneDx
Via Business Wire
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
From GeneDx
Via Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From GeneDx
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.